To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
7 Current news of U.S. Department of Defenserss
First sales of IXIARO under this military contract expected soon
Intercell AG announced that the Company has successfully entered into a multi-year contract with the Defense Logistics Agency (DLA), Defense Supply Center of the U.S. Department of Defense to supply IXIARO, a vaccine against Japanese Encephalitis (JE). The first sales of IXIARO under this ...
U.S. Department of Defense Agency Has Selected Peregrine for a Multi-Year Award That Could Total $44.5 Million Pending Successful Contract Negotiations
Peregrine Pharmaceuticals, Inc. announced that the company's proposal to investigate its antiviral agent bavituximab and other anti-phosphotidylserine (anti-PS) antibodies as potential therapies for hemorrhagic fever virus (HFV) infections has been selected for a contract award by the Defense ...
Parties Could Not Agree on Further Development and Commercialization
Applied Biosystems, an Applera Corporation business, announced that its contract with the U.S. Department of Defense surrounding the development of a prototype instrument system to improve the way infectious diseases are identified for epidemiological and biosecurity purposes has been ...
Four-Year Contract Funds Preclinical Development of Therapies to Combat Anthrax
Achaogen, Inc., a developer of antibacterial compounds, has executed a four-year contract with the Defense Threat Reduction Agency (DTRA), an agency of the United States Department of Defense, worth up to $24.7 million dollars for the development of therapies to treat anthrax and other ...
Medarex, Inc. and PharmAthene, Inc. announced that the FY 2007 Department of Defense (DoD) appropriations law includes $1.0 million payable to PharmAthene to support ongoing development of Valortim(TM), an investigational fully human monoclonal antibody being developed for the prevention and ...
Development of medical countermeasure to ricin
Twinstrand Therapeutics announced that it has been awarded a contract for research and development of a human polyclonal antibody (antidote) to ricin poisoning. The two-year $2.2 M CDN ($1.9 M USD) contract was granted, in a competitive process, by the United States Defense Threat Reduction ...
Applied Biosystems, an Applera Corporation business, announced that the U.S. Department of Defense has awarded the company a $24.5 million contract to accelerate the development of a prototype instrument system that is intended to improve the way infectious diseases are identified for ...